Immunotherapy in melanoma patients with autoimmune disease

doi:10.3760/cma.j.issn.1673-422X.2017.04.019

Abstract

Abstract: Immunotherapy has become an important treatment for melanoma. The anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4） antibody or programmed death-1 (PD-1)/programmed deathligand 1 (PD-L1) inhibitor is safe and effective for melanoma patients with autoimmune disease (AD). However, when such patients are treated with anti-CTLA-4 antibody or PD-1/PD-L1 inhibitors, their condition changes should be closely monitored to prevent and avoid possible AD progression and immune-related adverse events.

Key words: Melanoma, Immunotherapy, Autoimmune disease

Sun Chengyu, Xu Yuqing. Immunotherapy in melanoma patients with autoimmune disease[J]. Journal of International Oncology, 2017, 44(4): 310-312.

References

［1］ Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis［J］. BMC Med, 2015, 13: 211. DOI: 10.1186/s12916-015-0455-8. ［2］ Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer［J］. Anticancer Res, 2012, 32(4): 11191136. ［3］ Lopez-Olivo MA, Tayar JH, MartinezLopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis［J］. JAMA, 2012, 308(9): 898-908. DOI: 10.1001/2012.jama.10857. ［4］ Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden［J］. BMJ, 2013, 346: f1939. DOI: 10.1136/bmj.f1939. ［5］ Walker LS, Sansom DM. Confusing signals: recent progress in CTLA-4 biology［J］. Trends Immunol, 2015, 36(2): 63-70. DOI: 10.1016/j.it.2014.12.001. ［6］ Hall CJ, Doss S, Robertson J, et al. NICE guidance on ipilimumab for treating previously untreated advanced (unresectable or metastatic) melanoma［J］. Lancet Oncol, 2014, 15(10): 1056-1057.. ［7］ Hodi FS, O′Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma［J］. N Engl J Med, 2010, 363(8): 711-723. DOI: 10.1056/NEJMoa1003466. ［8］ Kyi C, Carvajal RD, Wolchok JD, et al. Ipilimumab in patients with melanoma and autoimmune disease［J］. J Immunother Cancer, 2013, 2(1): 35. DOI: 10.1186/s40425-014-0035-z. ［9］ Lee B, Wong A, Kee D, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma［J］. Ann Oncol, 2016, 27(6): 1174-1177. DOI: 10.1093/annonc/mdw056. ［10］ Pedersen M, Andersen R, N-rgaard P, et al. Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease［J］. Cancer Immunol Immunother, 2014, 63(12): 1341-1346. DOI: 10.1007/s00262-014-1607-y. ［11］ Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma［J］. Mult Scler, 2015, 21(5): 670. DOI: 10.1177/1352458514549403. ［12］ Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders［J］. JAMA Oncol, 2016, 2(2): 234-240. DOI: 10.1001/jamaoncol.2015.4368. ［13］ Borch TH, Donia M, Andersen MH, et al. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies［J］. Drug Discov Today, 2015, 20(9): 1127-1134. DOI: 10.1016/j.drudis.2015.07.003. ［14］ Spranger S, Spaapen RM, Zha Y, et al. Upregulation of PD-L1, IDO, and T (regs) in the melanoma tumor microenvironment is driven by CD8 (+) T cells［J］. Sci Transl Med, 2013, 5(200): 200ra116. DOI: 10.1126/scitranslmed.3006504. ［15］ Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance［J］. Nature, 2014, 515(7528): 568-571. DOI: 10.1038/nature13954. ［16］ Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma［J］. N Engl J Med, 2015, 372(26): 2521-2532. DOI: 10.1056/NEJMoa1503093. ［17］ Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blo-ckade in cancer therapy［J］. J Clin Oncol, 2015, 33(17): 1974-1982. DOI: 10.1200/JCO.2014.59.4358. ［18］ Beck KM, Dong J, Geskin LJ, et al. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid［J］. J Immunother Cancer, 2016, 4: 20. DOI: 10.1186/s40425-016-0123-3. ［19］ Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab［J］. Ann Oncol, 2016, pii: mdw443. DOI: 10.1093/annonc/mdw443.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[6]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[7]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[8]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Wu Minhang, Sun Wenzheng, Yu Qingzhuo, Guo Rong, Ye Hui, Du Ying, Qiu Jin, An Huazhang, Cao Lili. RNF43 inhibits PD-L1 expression via β-catenin in melanoma cells and promotes CD8⁺ T cell-mediated anti-tumor immune reaction [J]. Journal of International Oncology, 2023, 50(7): 407-412.
[11]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[14]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.
[15]	Ding Hao, Ying Jintao, Fu Maoyong. Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(4): 231-235.